Key clinical point: Erenumab demonstrated sustained efficacy and safety through 64 weeks in patients with episodic migraine (EM) with 2-4 prior preventive treatment failures.
Major finding: Overall, the proportion of patients achieving 50% or greater reduction in monthly migraine days increased from 30.4% at weeks 13-16 to 47.3% at weeks 37-40 and remained stable through weeks 61-64 (47.1%). Overall, 6.7% of patients experienced treatment-emergent serious adverse events and 1.7% discontinued treatment because of treatment-emergent adverse events.
Study details: Findings of the first year of the ongoing 3-year open-label extension phase of LIBERTY study that evaluated monthly erenumab 140 mg in 240 patients with EM who had 2-4 prior preventive treatment failures.
Disclosures: The study was funded by Novartis Pharma AG, Basel, Switzerland. Some of the authors reported receiving grants, professional fees, consulting fees, speaking/teaching fees, and/or honoraria from; being an employee of; and/or holding stocks in various pharmaceutical companies including Novartis.
Source: Goadsby PJ et al. Neurology. 2021 Apr 28. doi: 10.1212/WNL.0000000000012029 .